LOW-VOLUME · DEATH-HEAVY
rolapitant Side Effects
rolapitant (also sold as Varubi) is a LOW-VOLUME FAERS extract #507 of 524 by FAERS report count. Still opens on DEATH-HEAVY: 30.3% of FAERS reports list death as an outcome (161 of 531).
Data updated 2026-05-15
- 531
- FAERS reports
Thinner FAERS book - still a temporal association ledger, not proof of cause. Methodology.
rolapitant: 30.3% of FAERS reports list death as an outcome (161 of 531). Caseload stamp SIGNAL; volume band LOW-VOLUME #507 of 524 by FAERS report count.
Thinner FAERS extract for rolapitant (Varubi) (531 reports #507 of 524 by FAERS report count). 30.3% of FAERS reports list death as an outcome (161 of 531). Sparse books still carry named reaction rows when present; not medical advice.
Counts from the openFDA FAERS extract (2013–2025). Stamps SIGNAL · DEATH-HEAVY · HOSP-MID · SEX-BALANCED.
DEATH leads 141 of 531 reports
Who reports · age peak 45-64 (SEX-BALANCED)
Sex coding · SEX-BALANCED
Age peak 45-64 (120 reports)
Reporting taper since 2013 peak
Reactions in Death Reports
Death-mentioned subset is HEAVY here (161 reports, 30.3%). Top co-reported reactions in that subset - voluntary, not causal.
| Reaction | Reports |
|---|---|
| DEATH | 141 |
| ACUTE INTERSTITIAL PNEUMONITIS | 9 |
| RESPIRATORY SYMPTOM | 9 |
| NAUSEA | 5 |
| PNEUMONIA | 4 |
| THROMBOCYTOPENIA | 4 |
| ANAEMIA | 3 |
| HOSPITALISATION | 3 |
| NEOPLASM MALIGNANT | 3 |
| CONSTIPATION | 2 |
| DECREASED APPETITE | 2 |
| DEHYDRATION | 2 |
| DISEASE PROGRESSION | 2 |
| FATIGUE | 2 |
| HAEMOGLOBIN DECREASED | 2 |
| HEADACHE | 2 |
| HYPERKALAEMIA | 2 |
| MALAISE | 2 |
| WEIGHT DECREASED | 2 |
Reactions in Hospitalization Reports
Hospitalization mid-share (114, 21.5%). Co-reported reactions:
| Reaction | Reports |
|---|---|
| NAUSEA | 18 |
| DECREASED APPETITE | 12 |
| HOSPITALISATION | 12 |
| FATIGUE | 10 |
| DEATH | 9 |
| DIARRHOEA | 9 |
| THROMBOCYTOPENIA | 9 |
| DISEASE PROGRESSION | 7 |
| DYSPNOEA | 7 |
| MALAISE | 7 |
| PNEUMONIA | 7 |
| ASTHENIA | 6 |
| CHEST PAIN | 6 |
| CONSTIPATION | 6 |
| DEHYDRATION | 6 |
| PLASMA CELL MYELOMA | 6 |
| ANAEMIA | 5 |
| ARTHRALGIA | 5 |
| BLOOD COUNT ABNORMAL | 5 |
| CARDIAC FAILURE | 5 |
How to read rolapitant FAERS figures (SIGNAL · DEATH-HEAVY · HOSP-MID)
FAERS holds 531 voluntary reports linked to rolapitant (Varubi), 2013-2025. Death is listed on 161 (30.3%). Hospitalization appears on 114 (21.5%). Top co-reported indication: Nausea.
Sparse extract - named reactions and SEX-BALANCED skew still differ by drug; not a complete safety profile.
Read with rolapitant
Peers ranked by ABS(total_reports), then an ABS(death_share) pole; guide hop follows DEATH-HEAVY · HOSP-MID stamps.
ABS(total_reports) peer at 537 FAERS cases (Δ 6 heavier vs rolapitant); DEATH-HEAVY · HOSP-HEAVY · SEX-BALANCED vs this page's SIGNAL · DEATH-HEAVY · HOSP-MID · SEX-BALANCED.
ABS(total_reports) peer at 541 FAERS cases (Δ 10 heavier vs rolapitant); DEATH-HEAVY · HOSP-HEAVY · SEX-BALANCED vs this page's SIGNAL · DEATH-HEAVY · HOSP-MID · SEX-BALANCED.
ABS(total_reports) peer at 520 FAERS cases (Δ 11 lighter vs rolapitant); DEATH-HEAVY · HOSP-HEAVY · SEX-BALANCED vs this page's SIGNAL · DEATH-HEAVY · HOSP-MID · SEX-BALANCED.
ABS(total_reports) peer at 580 FAERS cases (Δ 49 heavier vs rolapitant); DEATH-HEAVY · HOSP-HEAVY · SEX-BALANCED vs this page's SIGNAL · DEATH-HEAVY · HOSP-MID · SEX-BALANCED.
ABS(death_share) pole at 62.1% death-mentioned reports (Δ 31.8 pp vs rolapitant's DEATH-HEAVY): CASELOAD · HOSP-MID.
rolapitant stamps DEATH-HEAVY · HOSP-MID; FAERS outcome shares are signal-detection rates, not incidence. Read them next to caseload SIGNAL and the label guide.